Latest News

Latest news from CARBOGEN AMCIS

Below, you will find the latest news from CARBOGEN AMCIS, the Dishman Group and the industry as a whole. For press inquiries or further information on any of the items below please contact us

If you are looking for more information on our latest expansion, please visit our Knowledge Centre

  • CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France

    Bubendorf, Switzerland (3 February 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a state-of-the-art facility in Saint-Beauzire, France.

    The new site is dedicated to the custom development and production of sterile injectable drug products. Built on newly acquired land located 7km from an existing CARBOGEN AMCIS site in Riom, the new...

  • CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    CARBOGEN AMCIS announces successful Swissmedic inspection at Vionnaz, Switzerland

    Bubendorf, Switzerland (Septembre 29, 2022) – Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that its site in Vionnaz, Switzerland has successfully completed a Swissmedic inspection performed by Regional Medicines Inspectorate of Western Switzerland (ISOPTh).

    The two-day inspection took place from September 20th to 21th, 2022 and was undertaken by an inspector of Regional Medicines Inspectorate of Western Switzerland...

  • CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    CARBOGEN AMCIS appointed new Vice President of Business Development, Sales & Marketing

    BUBENDORF, Switzerland (July 21, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the appointment of François Baduel as Vice President of Business Development, Sales & Marketing.

    In his new role, François Baduel will lead the company’s overall sales and marketing operations. He will report directly to Pascal Villemagne, Chief Executive Officer,...

  • Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April

    In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice President of Sales...

  • Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte...

  • NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    NH TherAguix announces the release of a new clinical batch for its drug AGuIX, manufactured by CARBOGEN AMCIS

    MEYLAN, France, BUBENDORF, Switzerland, (November 3rd, 2021) - NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and Drug Products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.

    CARBOGEN AMCIS just released the fifth batch of AGuIX Drug Product since inception of the company. The release of this 3.7 kg batch...

  • CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    CARBOGEN AMCIS announces successful FDA inspection of its facility in Aarau, Switzerland

    BUBENDORF, Switzerland (27 October 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at the site in Aarau, Switzerland.

    The pre-approval FDA paper inspection for an intermediate product from a customer was conducted from 17 August - 15 September 2021. By receiving the result in October 2021 the inspection was concluded successfully with no findings, confirming that...

  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

    BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.

    The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and is following a previous investment of CHF 6 million.

    The recent...

  • CARBOGEN AMCIS acquires new property at Bubendorf site

    CARBOGEN AMCIS acquires new property at Bubendorf site

    CARBOGEN AMCIS acquires new property at Bubendorf site

    • English

      BUBENDORF, Switzerland (24 June, 2021) Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the acquisition of a new property in Bubendorf.  

      CARBOGEN AMCIS confirms the acquisition of further property in Bubendorf (Basel-Landschaft), where the company's headquarters are located. The property in Hauptstrasse 175 has been acquired from the previous owners Marcel und Theres Rutschmann and...

  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

    BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build  a site extension at the Bubendorf site in Switzerland.  

    The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will...

  • Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency  (2)

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency (2)

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency

    Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN...

  • CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    • English

      BUBENDORF, Switzerland (August 17, 2020) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France. 

      CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities,...

  • COVID-19

    COVID-19

    COVID-19

    • English

      Dear Customers and Partners,

      We at Dishman Carbogen Amcis group of companies are taking the risks associated with COVID-19 very seriously, and have already implemented a set of measures aimed at limiting any risk to our employees, customers and patients. We have already established a dedicated working team who monitor the COVID-19 outbreak and all processes have been analyzed with regards to risks. This allows us to have all our operations running smoothly and we currently do not have an impact on our operations.

      We are facing a unique situation in several of the...

  • Successful FDA Inspection at Neuland, Switzerland

    Successful FDA Inspection at Neuland, Switzerland

    BUBENDORF, Switzerland (August 6, 2019) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today its Hunzenschwil (Neuland), Switzerland API manufacturing site has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection. 

    The four-day, pre-approval inspection was undertaken by an FDA investigator from July 8-11, 2019. The inspection was concluded with no Form 483’s filed, thus confirming that no critical or major observation was raised...

  • ISO22716 Cosmetics GMP standard accreditation

    ISO22716 Cosmetics GMP standard accreditation

    BUBENDORF, Switzerland (May 22nd, 2019) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today that its Manchester site successfully passed the accreditation for the ISO22716 Cosmetics GMP standard. 

    CARBOGEN AMCIS Ltd (Manchester) successfully passed two stages of audit in December 2018 and in March 2019 by a third-party certification body conducted by Lloyd's Register Quality Assurance Limited. The audit sessions were to assess the compliance of the Quality Management System...

  • Dishman Carbogen Amcis Opens Office in Kyoto, Japan

    Dishman Carbogen Amcis Opens Office in Kyoto, Japan

    BUBENDORF, Switzerland (August 1st, 2018) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the opening of their new Japanese office, located in Kyoto. 

    The opening of Dishman Carbogen Amcis Japan Ltd. marks yet another stepping stone for Dishman Carbogen Amcis, already actively serving the Japanese market for active pharmaceutical ingredients (APIs) development and commercialization services through its Swiss entity CARBOGEN AMCIS AG.

    The new...

  • CARBOGEN AMCIS Announces a Successful Swissmedic Inspection of its Site in Vionnaz, Switzerland

    CARBOGEN AMCIS Announces a Successful Swissmedic Inspection of its Site in Vionnaz, Switzerland

    BUBENDORF, Switzerland (February 16, 2018) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today that its Vionnaz site has successfully completed a Swissmedic inspection.

    Swissmedic conducted the inspection (general surveillance audits) over two days, on December 12-13, 2017 at CARBOGEN AMCIS’ Vionnaz site. The inspection covered the Quality System related to the development and manufacture of highly potent APIs, including...

  • CARBOGEN AMCIS Announces a Successful FDA Inspection of its Headquarters Site in Bubendorf, Switzerland

    CARBOGEN AMCIS Announces a Successful FDA Inspection of its Headquarters Site in Bubendorf, Switzerland

    CARBOGEN AMCIS Announces a Successful FDA Inspection of its Headquarters Site in Bubendorf, Switzerland

    BUBENDORF, Switzerland (October 11th, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today that its Bubendorf, Switzerland API manufacturing site has successfully completed a routine U.S. Food and Drug Administration (FDA) inspection.

    The cGMP (current Good Manufacturing Practices) Audit was completed over five days, from September 4th to 8th, 2017. The inspection consisted of an analysis of all Quality Systems,...

  • CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection

    CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection

    CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection

    BUBENDORF, Switzerland (July 21st, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced the renewal of cGMP certificates, and the successful completion of Swissmedic inspections at three of its sites. 

    Swissmedic conducted inspections (general surveillance audits) of three of CARBOGEN AMCIS' facilities – Bubendorf, Aarau and Neuland – in late April and early May, 2017. No significant concerns were...

  • Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

    Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

    Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

    AHMEDABAD, INDIA, August 11, 2016 – Dishman Pharmaceuticals and Chemicals Ltd (DPCL), leading outsourcing partner for the global pharmaceutical industry, today marked the 10-year anniversary of its acquisition of CARBOGEN AMCIS. A significant milestone of growth and development of Indian-Swiss business relations.
     
    CARBOGEN AMCIS (headquarters in Bubendorf, Switzerland) and Dishman Pharmaceuticals and Chemicals Ltd (headquarters in Ahmedabad, India) are both suppliers of complex services and products for the global pharmaceutical industry....

  • CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection

    CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection

    CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection

    BUBENDORF, Switzerland (July 13th, 2016) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced, after reception of the Establishment Inspection Report (EIR), that two of its Swiss sites have successfully completed a U.S. Food and Drug Administration (FDA) inspection.

    The Pre-Approval Inspections (PAIs) have been completed by an FDA inspector over four days: October 19-20, 2015 in Aarau and October 21 – 22, 2015 in Neuland. The...

  • CARBOGEN AMCIS Expands Operations in Bubendorf

    CARBOGEN AMCIS Expands Operations in Bubendorf

    CARBOGEN AMCIS Expands Operations in Bubendorf

    BUBENDORF, Switzerland (May 31st, 2016) — CARBOGEN AMCIS, the Swiss-based company offering process development and manufacturing of Active Pharmaceutical Ingredient (API) to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
     
    On May 26th, 2016, we (CARBOGEN AMCIS) have undersigned the acquisition of the land and buildings of GEA Pharma Systems AG in Bubendorf, Hauptstrasse 145. The acquisition close to our current headquarters will become effective on Jan. 1st, 2017.
     
    Located on 5’200 m²...

  • CARBOGEN AMCIS Passes Successful Inspection by Swissmedic

    CARBOGEN AMCIS Passes Successful Inspection by Swissmedic

    CARBOGEN AMCIS Passes Successful Inspection by Swissmedic

    CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced a successful inspection by Swissmedic of its recently acquired site in Vionnaz, Switzerland.

    The site has been inspected by Swissmedic and by the U.S. Food and Drug Administration (FDA) in the past and the re-audit is due to the change of ownership. The two-and-a-half-day audit covered the Quality System related to development and manufacture of highly potent APIs at the Vionnaz facility, including Analytical and...

  • CARBOGEN AMCIS CEO Mark Griffiths Appointed to Dishman Board of Directors

    CARBOGEN AMCIS CEO Mark Griffiths Appointed to Dishman Board of Directors

    CARBOGEN AMCIS CEO Mark Griffiths Appointed to Dishman Board of Directors

    CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that Mark C. Griffiths, global chief executive officer of Dishman and CARBOGEN AMCIS, has joined the board of directors of Dishman Pharmaceuticals and Chemicals Ltd.

    The appointment was made public by Shri Arpit J. Vyas, managing director,Dishman Pharmaceuticals and Chemicals Ltd.“We are excited to welcome Mark to the board of Dishman. Mark’s leadership at...

  • CARBOGEN AMCIS Expands Operations in Switzerland

    CARBOGEN AMCIS Expands Operations in Switzerland

    CARBOGEN AMCIS Expands Operations in Switzerland

    CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced plans to take over operations of a high-containment facility located in Vionnaz, Switzerland, 70 kilometers East of Geneva:

    CARBOGEN AMCIS │ Route du Simplon 24 │ CH-1895 Vionnaz │ Switzerland

    The high potency facility in Vionnaz opened in December 2005 and was formerly managed by Bachem AG as an integrated part of their site in Vionnaz....

  • CARBOGEN AMCIS AG Continues to Invest in Expanding High Potency Capabilities

    CARBOGEN AMCIS AG Continues to Invest in Expanding High Potency Capabilities

    CARBOGEN AMCIS AG Continues to Invest in Expanding High Potency Capabilities

    To meet rising demand for highly potent active pharmaceutical ingredients (APIs) spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Switzerland-based CARBOGEN AMCIS AG today announced that it has completed a capital investment project to upgrade its high potency capabilities. An industry leader in the production of high potency APIs, CARBOGEN AMCIS offers drug developers the full range of high potency services, from development, manufacturing and chromatography, to antibody drug conjugates (ADCs), fill &...

  • CARBOGEN AMCIS AG Makes Capital Investments in ADC

    CARBOGEN AMCIS AG Makes Capital Investments in ADC

    Switzerland-based CARBOGEN AMCIS AG announces a series of significant investments aimed at enhancing its antibody drug conjugate (ADC) capabilities to better respond to increasing demand for ADCs in the development of highly targeted cancer treatments. The investments include a $4 million USD clean room clinical supply facility at the Bubendorf, Switzerland site and a $950,000 USD upgrade of the sterile manufacturing area at the facility in Riom, France. By adding on to the current High Potency facility, CARBOGEN AMCIS is well positioned to offer its partners seamless development and...